Interim Report – January to June 2014

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech Company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its report for the second quarter 2014.

Financial Highlights

• Revenue for the 2nd quarter 2014 SEK 12.0 (10.8) million, and for the six month period to 21.9 (23.1) million
• Operating result for the period amounted to SEK -0.8 (-2.4) million, and for the six month period to -3.7 (-0.7) million
• EBITDA for the period amounted to SEK -0.7 (-2.3) million, and for the six month period to -3.4 (-0.6) million
• Net result for the period amounted to SEK -1.2 (-2.6) million, and for the six month period to -4.3 (-1.4) million
• Cash flow for the period was SEK -1.8 (-3.8) million, and for the six month period to -3.7 (-3.5) million
• Cash and cash equivalents at the end of the period amounted to SEK 29.4 (17.8) million

Significant events during the second quarter

• The first patient was included in a PET Imaging Study of HER2 Expression in Breast Cancer at Herlev University Hospital
• An Annual General Meeting on May 8 elected Håkan Åström, Jakob Lindberg, Mathias Uhlén and Jonathan Knowles as Directors of the Board

Other significant events during 2014

• Investor AB acquired all HealthCap’s shares in Affibody